Corning Jerry appoints Han Jing as chief commercial officer

Suzhou, November 2, 2021/PRNewswire/ - Corning Jereh Biopharmaceuticals (stock code: 9966.
HK) announced the appointment of Mr.
Han Jing as Chief Commercial Officer, responsible for the company’s commercialization and promotion, and reported to the company’s chairman and chairman of the board.
President Dr.
Xu Ting reports
.

Mr.
Han Jing

Mr.
Han Jing has been deeply involved in the Chinese pharmaceutical market for more than 20 years.
He has served in world-renowned multinational pharmaceutical companies including Merck, Boehringer Ingelheim, AstraZeneca, Bayer, Roche, and Chinese innovative biopharmaceutical companies such as Junshi Biologics.
in the formation and leadership of business team, development and implementation of business strategy has accumulated a wealth of experience
.

Before joining Corning Jerry, Mr.

Dr.
Xu Ting, Chairman and President of Corning Jereh, said: "Welcome Mr.
Han Jing to join Corning Jereh
.

Since the establishment of the company, we have always been committed to building an innovative biopharmaceutical company with a full industry chain and international competitiveness

Mr.
Han Jing, Chief Commercial Officer of Corning Jereh, said: "In the ever-changing wave of Chinese biopharmaceutical innovation, Corning Jereh is undoubtedly a bright star.
Under the leadership of Chairman Xu Ting, the company has created various multifunctional antibodies.
The development platform integrates excellent R&D and production technology
.

I very much recognize the chairman and the company's mission of "making tumors a controllable and curable disease" and the strategy of "based on China and looking at the world".

Mr.
Han Jing graduated from the Department of Clinical Medicine of Shanghai Second Medical University in 1996 and began to work as a general surgeon until he chose to join Merck in 1998 and started his career in pharmaceutical companies for more than 20 years
.

In 2018, Mr.

About Corning Jerry

Corning Jereh Biopharmaceuticals focuses on the research and development, production and commercialization of innovative anti-tumor drugs
.

On December 12, 2019, the company was listed on the main board of the Hong Kong Stock Exchange, stock code: 9966

Corning Jereh Biopharmaceuticals has a discovery, R&D, and manufacturing platform for the entire industry chain in bispecific antibody and protein engineering
.

The company's product pipeline includes 15 highly differentiated anti-tumor drug candidates with independent intellectual property rights, mainly double antibodies, and a Covid-19 multifunctional antibody, four of which are in China, the United States, Japan, and Australia It is in clinical phase I-III

The company has a number of technical platforms with independent intellectual property rights such as heterodimers and hybrid antibodies, and large-scale production capabilities that meet the cGMP standards of China, the United States and the European Union, and have passed a complete quality system including multiple audits of the European Union QP.

.

The company is committed to building a world-leading, multi-dimensional drug development and industrialization platform, focusing on multifunctional biomacromolecule new drugs, benefiting patients in China and around the world